← Eichor
Study identifier: NCT04766866 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term.

Condition: Preeclampsia · Intrauterine Growth Restriction · Maternal Hypertension  ·  Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

PhaseNA
Planned participants9132
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersYes

About this study

* Preeclampsia (PE) affects \~5% of pregnancies. Although improved obstetrical care has significantly diminished associated maternal mortality, PE remains a leading cause of maternal morbidity and mortality in the world. * Term PE accounts for 70% of all PE and a large proportion of maternal-fetal morbidity related with this condition. Prediction and prevention of term PE remains unsolved. * Previously proposed approaches are based on combined screening and/or prophylactic drugs, but these policies are unlikely to be implementable in many world settings. * Recent evidence shows that sFlt1-PlGF ratio at 35-37w predicts term PE with 80% detection rate. * Likewise, recent studies demonstrate that induction of labor (IOL) from 37w is safe. * The investigators hypothesize that a single-step universal screening for term PE based on sFlt1/PlGF ratio at 35-37w followed by IOL from 37w would reduce the prevalence of term PE without increasing cesarean section rates or adverse neonatal outcomes. * The investigators propose a randomized clinical trial to evaluate the impact of a screening of term PE with sFlt-1/PlGF ratio in asymptomatic nulliparous women at 35-37w. Women will be assigned to revealed (sFlt-1/PlGF known to clinicians) versus concealed (unknown) arms. A cutoff of \>90th centile will be used to define high risk of PE and offer IOL from 37w. * If successful, the results of this trial will provide evidence to support a simple universal screening strategy reducing the prevale…

This description comes directly from the study's public registry record.

Talk to the study team

Elisa Llurba, MD; PhD  ·  0034687743699  ·  ellurba@santpau.cat

Always discuss trial participation with your own doctor first.

Locations (21)

CHU LiègeLiège, BelgiumActive Not Recruiting
Clinica del Prado SASBogotá, ColombiaRecruiting
Institute for the Care of Mother and ChildPrague, CzechiaActive Not Recruiting
Medicina Fetal QuitoQuito, EcuadorRecruiting
Maulana Azad Medical College (MAMC)New Delhi, National Capital Territory of Delhi, IndiaRecruiting
All India Institute of Medical Sciences (AIIMS) Ansari NagarNew Delhi, National Capital Territory of Delhi, IndiaRecruiting
Vardhman Mahavir Medical College (VMMC)New Delhi, National Capital Territory of Delhi, IndiaRecruiting
Hospital Gineco-Obstetricia nº4Mexico City, MexicoNot Yet Recruiting
Hospital Santo TomasPanama City, PanamaRecruiting
Centre of Postgraduate Medical Education, Obstetrics and Gynecology and Perinatal MedicineWarsaw, PolandActive Not Recruiting
Hospital Germans Trias i PujolBadalona, Barcelona, SpainActive Not Recruiting
Complejo Hospitalario Universitario Insular Materno InfantilLas Palmas de Gran Canaria, Canary Islands, SpainWithdrawn

+ 9 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04766866